|
Clinical Question: In patient with Type 2 Diabetes
Mellitus, which is more effective Nateglinide or Repaglinide?
Bottom Line: The glucose lowering effect of repaglinide at a dosing
level of 1.0 mg tid was better than that of nateglinide 90 mg tid on fasting
blood glucose and A1c during 12 weeks treatment period, yet the
insulinotropic effects of the two drugs were similar.
Reference: Sichuan Da Xue Xue Bao Yi Xue Ban. 2005
Mar;36(2):267-70.Comparison of efficacy between nateglinide and repaglinide
in treating type 2 diabetes: a randomized controlled double-blind clinical
trial, Li JW, Tian HM, Yu HL, Zhang XX, Zhao GZ, Wang JN.
Study Design: Randomized controlled double-blind clinical
trial
Synopsis: To compare the efficacy of nateglinide with
repaglinide in the treatment of type 2 diabetes mellitus. Forty-six type 2
diabetic patients were randomly treated with repaglinide (group A, 1.0 mg
tid, n=23) or nateglinide (group B, 90.0 mg tid, n=23). The trial consisted
of a 4-week equilibrated period followed by 12 weeks of treatment course. In
group A, the fasting blood glucose (FBG) and 30-, 60-, 120- min postprandial
blood glucose (PBG), as well as hemoglobin A1c were decreased significantly
(P<0.05). In group B, the 60-min and 120-min PBG decreased remarkably
(P<0.05), but FBG, 30-min PBG and A1c decreased with no statistical
significance (P>0.05). After 12 weeks treatment, the 30-, 60-, 120-min
postprandial insulin level, area under the curve of insulin and C peptide (0
to 120 min) increased in both groups (P<0.05). No significant difference was
found between the effects of repaglinide and nateglinide on early phase
insulin secretion.
|